Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer
Introduction: Mirvetuximab soravtansine (MIRV) recently emerged as a promising therapeutic option for patients with platinum resistant ovarian cancer (PROC). In trials leading up to its approval, several ocular and other toxicities were identified. We report our experience with MIRV in a less-select...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Gynecologic Oncology Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2352578925000633 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849423126644916224 |
|---|---|
| author | Susan M. Lang Filippos Vingopoulos Isabel Beshar Sahana Somasegar Elizabeth V. Adams Simone A. Sasse Talayeh Ghezelayagh Emily Clair McClung Amer Karam Oliver Dorigo Prithvi Mruthyunjaya Babak Litkouhi |
| author_facet | Susan M. Lang Filippos Vingopoulos Isabel Beshar Sahana Somasegar Elizabeth V. Adams Simone A. Sasse Talayeh Ghezelayagh Emily Clair McClung Amer Karam Oliver Dorigo Prithvi Mruthyunjaya Babak Litkouhi |
| author_sort | Susan M. Lang |
| collection | DOAJ |
| description | Introduction: Mirvetuximab soravtansine (MIRV) recently emerged as a promising therapeutic option for patients with platinum resistant ovarian cancer (PROC). In trials leading up to its approval, several ocular and other toxicities were identified. We report our experience with MIRV in a less-selected “real-world” population. Methods: A retrospective review of patients with folate-receptor alpha positive, recurrent PROC treated with MIRV between December 2022-April 2024 was performed. Demographic, treatment, and toxicity data were abstracted from the medical record. The primary outcomes of interest were the incidence and nature of MIRV-related toxicities, as well as the clinical response to treatment. Results: 25 patients were analyzed, and 44 % had >3 previous lines of treatment. The median duration of MIRV treatment 4.7 months, and 36 % of patients received more than 6 months of MIRV. Ocular events were common and occurred early, resulting in grade 1, 2, and 3 toxicity (28 %, 20 %, and 16 % respectively). As a result, 36 % of patients had an increased frequency of ophthalmologic care, 48 % required a medication change, and 32 % had dose reduction, but none required MIRV discontinuation. Pneumonitis occurred in 24 % of patients, was the leading cause of treatment discontinuation and may be associated with significant underlying cardiopulmonary comorbidities and pulmonary disease burden. Conclusion: Our real-world experience with MIRV mirrors previously published data and suggests a benefit may also be seen in a more heavily pretreated population. Toxicities were similar to those previously reported, although our increased incidence of pneumonitis suggests care when treating patients with significant underlying cardiopulmonary comorbidities. |
| format | Article |
| id | doaj-art-71642ca2bb6f4b3cbb9379b42610bf9d |
| institution | Kabale University |
| issn | 2352-5789 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Gynecologic Oncology Reports |
| spelling | doaj-art-71642ca2bb6f4b3cbb9379b42610bf9d2025-08-20T03:30:47ZengElsevierGynecologic Oncology Reports2352-57892025-06-015910173810.1016/j.gore.2025.101738Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancerSusan M. Lang0Filippos Vingopoulos1Isabel Beshar2Sahana Somasegar3Elizabeth V. Adams4Simone A. Sasse5Talayeh Ghezelayagh6Emily Clair McClung7Amer Karam8Oliver Dorigo9Prithvi Mruthyunjaya10Babak Litkouhi11Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Stanford University, 453 Quarry Road, Palo Alto, CA 94304, USA; Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Stony Brook Medicine, Stony Brook, NY 11794, USADepartment of Ophthalmology, Byers Eye Institute at Stanford, 2452 Watson Court, Palo Alto, CA 94303, USADepartment of Obstetrics & Gynecology, Stanford University, 453 Quarry Road, Palo Alto, CA 94304, USA; Corresponding author at: Stanford Department of Obstetrics & Gynecology, Stanford University, Center for Academic Medicine, 453 Quarry Road, Palo Alto, CA 94304, USA.Division of Gynecology Oncology, Department of Obstetrics & Gynecology, Stanford University, 453 Quarry Road, Palo Alto, CA 94304, USADivision of Gynecology Oncology, Department of Obstetrics & Gynecology, Stanford University, 453 Quarry Road, Palo Alto, CA 94304, USADivision of Gynecology Oncology, Department of Obstetrics & Gynecology, Stanford University, 453 Quarry Road, Palo Alto, CA 94304, USADivision of Gynecology Oncology, Department of Obstetrics & Gynecology, Stanford University, 453 Quarry Road, Palo Alto, CA 94304, USADivision of Gynecology Oncology, Department of Obstetrics & Gynecology, Stanford University, 453 Quarry Road, Palo Alto, CA 94304, USADivision of Gynecology Oncology, Department of Obstetrics & Gynecology, Stanford University, 453 Quarry Road, Palo Alto, CA 94304, USADivision of Gynecology Oncology, Department of Obstetrics & Gynecology, Stanford University, 453 Quarry Road, Palo Alto, CA 94304, USADepartment of Ophthalmology, Byers Eye Institute at Stanford, 2452 Watson Court, Palo Alto, CA 94303, USADivision of Gynecology Oncology, Department of Obstetrics & Gynecology, Stanford University, 453 Quarry Road, Palo Alto, CA 94304, USAIntroduction: Mirvetuximab soravtansine (MIRV) recently emerged as a promising therapeutic option for patients with platinum resistant ovarian cancer (PROC). In trials leading up to its approval, several ocular and other toxicities were identified. We report our experience with MIRV in a less-selected “real-world” population. Methods: A retrospective review of patients with folate-receptor alpha positive, recurrent PROC treated with MIRV between December 2022-April 2024 was performed. Demographic, treatment, and toxicity data were abstracted from the medical record. The primary outcomes of interest were the incidence and nature of MIRV-related toxicities, as well as the clinical response to treatment. Results: 25 patients were analyzed, and 44 % had >3 previous lines of treatment. The median duration of MIRV treatment 4.7 months, and 36 % of patients received more than 6 months of MIRV. Ocular events were common and occurred early, resulting in grade 1, 2, and 3 toxicity (28 %, 20 %, and 16 % respectively). As a result, 36 % of patients had an increased frequency of ophthalmologic care, 48 % required a medication change, and 32 % had dose reduction, but none required MIRV discontinuation. Pneumonitis occurred in 24 % of patients, was the leading cause of treatment discontinuation and may be associated with significant underlying cardiopulmonary comorbidities and pulmonary disease burden. Conclusion: Our real-world experience with MIRV mirrors previously published data and suggests a benefit may also be seen in a more heavily pretreated population. Toxicities were similar to those previously reported, although our increased incidence of pneumonitis suggests care when treating patients with significant underlying cardiopulmonary comorbidities.http://www.sciencedirect.com/science/article/pii/S2352578925000633 |
| spellingShingle | Susan M. Lang Filippos Vingopoulos Isabel Beshar Sahana Somasegar Elizabeth V. Adams Simone A. Sasse Talayeh Ghezelayagh Emily Clair McClung Amer Karam Oliver Dorigo Prithvi Mruthyunjaya Babak Litkouhi Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer Gynecologic Oncology Reports |
| title | Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer |
| title_full | Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer |
| title_fullStr | Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer |
| title_full_unstemmed | Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer |
| title_short | Early experience and assessment of real-world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer |
| title_sort | early experience and assessment of real world toxicities with mirvetuximab soravtansine in a heavily pretreated patient cohort with ovarian cancer |
| url | http://www.sciencedirect.com/science/article/pii/S2352578925000633 |
| work_keys_str_mv | AT susanmlang earlyexperienceandassessmentofrealworldtoxicitieswithmirvetuximabsoravtansineinaheavilypretreatedpatientcohortwithovariancancer AT filipposvingopoulos earlyexperienceandassessmentofrealworldtoxicitieswithmirvetuximabsoravtansineinaheavilypretreatedpatientcohortwithovariancancer AT isabelbeshar earlyexperienceandassessmentofrealworldtoxicitieswithmirvetuximabsoravtansineinaheavilypretreatedpatientcohortwithovariancancer AT sahanasomasegar earlyexperienceandassessmentofrealworldtoxicitieswithmirvetuximabsoravtansineinaheavilypretreatedpatientcohortwithovariancancer AT elizabethvadams earlyexperienceandassessmentofrealworldtoxicitieswithmirvetuximabsoravtansineinaheavilypretreatedpatientcohortwithovariancancer AT simoneasasse earlyexperienceandassessmentofrealworldtoxicitieswithmirvetuximabsoravtansineinaheavilypretreatedpatientcohortwithovariancancer AT talayehghezelayagh earlyexperienceandassessmentofrealworldtoxicitieswithmirvetuximabsoravtansineinaheavilypretreatedpatientcohortwithovariancancer AT emilyclairmcclung earlyexperienceandassessmentofrealworldtoxicitieswithmirvetuximabsoravtansineinaheavilypretreatedpatientcohortwithovariancancer AT amerkaram earlyexperienceandassessmentofrealworldtoxicitieswithmirvetuximabsoravtansineinaheavilypretreatedpatientcohortwithovariancancer AT oliverdorigo earlyexperienceandassessmentofrealworldtoxicitieswithmirvetuximabsoravtansineinaheavilypretreatedpatientcohortwithovariancancer AT prithvimruthyunjaya earlyexperienceandassessmentofrealworldtoxicitieswithmirvetuximabsoravtansineinaheavilypretreatedpatientcohortwithovariancancer AT babaklitkouhi earlyexperienceandassessmentofrealworldtoxicitieswithmirvetuximabsoravtansineinaheavilypretreatedpatientcohortwithovariancancer |